RAB-006

RAB-006 is a preclinical-stage, on-demand sustained-release glucocorticoid formulation being developed by Zhongshan Lebo Ruichen Biopharmaceutical (Rabpharma) for the treatment of osteoarthritis. Designed for intra-articular administration, the drug utilizes a specialized controlled-release system to deliver anti-inflammatory glucocorticoid effects directly into the joint space. The "on-demand" mechanism is intended to regulate the release of the active ingredient based on physiological needs within the joint, aiming to provide prolonged therapeutic efficacy and improved safety by minimizing systemic exposure. It is part of a broader pipeline of bone and joint-targeted therapeutics developed by the company.